jcm-logo

Journal Browser

Journal Browser

Advancements and Future Directions in Clinical Psychosis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Mental Health".

Deadline for manuscript submissions: 10 February 2026 | Viewed by 147

Special Issue Editors


E-Mail Website
Co-Guest Editor
Unit of Epidemiological Psychiatry and Digital Mental Health, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
Interests: rehabilitation; recovery; supported accommodation; social psychiatry; digital health; epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Special Issue "Advancements and Future Directions in Clinical Psychosis" aims at addressinh the evolving landscape of psychosis research by highlighting recent breakthroughs and identifying critical challenges in clinical practice. Despite progress in neurobiological understanding, diagnostics, and therapeutic interventions, psychosis remains a complex and heterogeneous condition with significant unmet needs. Core problems include early detection, treatment resistance, and long-term functional outcomes. This collection seeks contributions that explore innovative diagnostic tools, personalized treatment strategies, neurocognitive and psychosocial approaches, and digital or AI-assisted interventions.

The scope encompasses original research, clinical trials, reviews, and translational studies focused on the schizophrenia spectrum and other psychotic disorders. Emphasis will be placed on interdisciplinary perspectives that bridge gaps between neuroscience, psychiatry, and public health.

Researchers, clinicians, and mental health professionals are encouraged to contribute their findings to foster collaborative advancement and shape future clinical frameworks. Through this mobilization, this Special Issue aspires to inform best practices and stimulate next-generation solutions in psychosis care.

You may choose our Joint Special Issue in Brain Sciences.

Dr. Marco Colizzi
Dr. Alessandra Martinelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical psychosis
  • schizophrenia spectrum disorders
  • early detection of psychosis
  • treatment-resistant psychosis
  • long-term outcomes
  • personalized psychiatry
  • digital mental health
  • AI in psychiatry
  • neurocognitive interventions
  • psychosocial therapies
  • translational psychiatry
  • interdisciplinary mental health
  • psychosis clinical trials
  • innova-tive diagnostic tools

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 3483 KB  
Review
UHPLC-MS/MS for Antipsychotic Drug Monitoring: A Systematic Review of Clinical and Analytical Performance
by Ciprian-Ionuț Băcilă, Bianca-Maria Macavei, Monica Cornea, Bogdan Ioan Vintilă, Andrei Lomnășan, Claudia Elena Anghel, Andreea Maria Grama, Cristina Elena Dobre, Claudia Marina Ichim and Gabriela Cioca
J. Clin. Med. 2025, 14(21), 7544; https://doi.org/10.3390/jcm14217544 (registering DOI) - 24 Oct 2025
Abstract
Background/Objectives: Therapeutic drug monitoring (TDM) of antipsychotic medications plays an important role in optimizing treatment efficacy, reducing adverse effects, and supporting adherence. While Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry (UHPLC–MS/MS) has long been the gold standard for antipsychotic quantification, recent advances in [...] Read more.
Background/Objectives: Therapeutic drug monitoring (TDM) of antipsychotic medications plays an important role in optimizing treatment efficacy, reducing adverse effects, and supporting adherence. While Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry (UHPLC–MS/MS) has long been the gold standard for antipsychotic quantification, recent advances in automated platforms and microsampling raise questions about its current clinical practicality. This systematic review evaluated the clinical applicability and analytical performance of UHPLC-based methods for monitoring antipsychotic drugs, focusing on precision, recovery, matrix effects, and suitability across various biological matrices. Methods: A systematic search of PubMed, Scopus, and Web of Science was conducted for studies published between 2013 and 2024 involving UHPLC-based quantification of antipsychotics in clinical samples from adult patients. Data on analytical parameters, sample matrices, and study characteristics were extracted. A custom quality checklist was used to assess methodological rigor. In addition to qualitative synthesis, non-traditional quantitative approaches were applied, including descriptive aggregation of recovery, matrix effects, and precision across studies, as well as correlation analyses to explore relationships among performance parameters. Results: Twelve studies were included, spanning a range of typical and atypical antipsychotics and metabolites. Plasma and serum demonstrated the highest analytical reliability (recovery >90%, minimal matrix effects), while dried blood spots (DBSs), whole blood, and oral fluid showed greater variability. Clinically, UHPLC–MS/MS enabled more accurate dose adjustments and identification of non-adherence, outperforming immunoassays in sensitivity, specificity, and metabolite detection. Microsampling methods showed promise for outpatient and decentralized care but require further clinical validation. Conclusions: UHPLC–MS/MS remains the most robust and reliable method for TDM of antipsychotics, especially when quantification of active metabolites is required. While logistical barriers remain, technological advances may enhance feasibility and support broader integration into routine psychiatric care. Full article
(This article belongs to the Special Issue Advancements and Future Directions in Clinical Psychosis)
Show Figures

Figure 1

Back to TopTop